

James W Wells

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6997901/publications.pdf>

Version: 2024-02-01

68
papers

2,064
citations

279798

23
h-index

265206

42
g-index

70
all docs

70
docs citations

70
times ranked

4129
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of AAV2.5 neutralizing antibodies in synovial fluid and serum of patients with osteoarthritis. <i>Gene Therapy</i> , 2022, , .	4.5	2
2	Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy. <i>Journal of Immunology</i> , 2021, 206, 987-998.	0.8	16
3	Investigating T Cell Immunity in Cancer: Achievements and Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2907.	4.1	12
4	Healing of sub-critical femoral osteotomies in mice is unaffected by tacrolimus and deletion of recombination activating gene 1. , 2021, 41, 345-354.		1
5	IFN- γ Critically Enables the Intratumoural Infiltration of CXCR3+ CD8+ T Cells to Drive Squamous Cell Carcinoma Regression. <i>Cancers</i> , 2021, 13, 2131.	3.7	7
6	Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions. <i>Vaccines</i> , 2021, 9, 535.	4.4	38
7	Abstract 1443: CHK1 inhibitor +low dose hydroxyurea triggers immunogenic cell death and immunostimulatory cytokine expression to drive an anti-tumor immune response. , 2021, , .		0
8	PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy. <i>Cancers</i> , 2021, 13, 3310.	3.7	7
9	Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. <i>Cancers</i> , 2021, 13, 3733.	3.7	12
10	Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial. <i>PLoS ONE</i> , 2021, 16, e0255282.	2.5	10
11	Peripheral Tolerance Checkpoints Imposed by Ubiquitous Antigen Expression Limit Antigen-Specific B Cell Responses under Strongly Immunogenic Conditions. <i>Journal of Immunology</i> , 2020, 205, 1239-1247.	0.8	9
12	Transfer of antigen-encoding bone marrow under immune-preserving conditions deletes mature antigen-specific B cells in recipients and inhibits antigen-specific antibody production. <i>Cytotherapy</i> , 2020, 22, 436-444.	0.7	0
13	Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. <i>PLoS Medicine</i> , 2020, 17, e1003024.	8.4	62
14	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , 2020, 180, 895-914.e27.	28.9	127
15	Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. <i>Science Advances</i> , 2020, 6, eaax2285.	10.3	85
16	Abstract B12: Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition. , 2020, , .		0
17	Editorial: Insights Into Biomarkers, Cytokines, and Chemokines in Skin Cancer. <i>Frontiers in Medicine</i> , 2019, 6, 199.	2.6	0
18	<i>Bacillus anthracis</i> Protective Antigen Shows High Specificity for a UV Induced Mouse Model of Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2019, 6, 22.	2.6	1

#	ARTICLE	IF	CITATIONS
19	Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage. <i>Scientific Reports</i> , 2019, 9, 17754.	3.3	11
20	An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. <i>Journal of Investigative Dermatology</i> , 2019, 139, 213-223.	0.7	19
21	Tetramer-based identification of naive antigen-specific B cells within a polyclonal repertoire. <i>European Journal of Immunology</i> , 2018, 48, 1251-1254.	2.9	16
22	Re-educating immunity in respiratory allergies: the potential for hematopoietic stem cell-mediated gene therapy. <i>Journal of Molecular Medicine</i> , 2018, 96, 21-30.	3.9	2
23	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	2.6	67
24	The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 271.	2.6	123
25	Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8 ⁺ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma. <i>OncImmunology</i> , 2018, 7, e1479627.	4.6	16
26	Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. <i>Oncotarget</i> , 2018, 9, 12250-12260.	1.8	11
27	Liposomal formulation of polyacrylate-peptide conjugate as a new vaccine candidate against cervical cancer. <i>Precision Nanomedicine</i> , 2018, 1, 183-193.	0.8	8
28	Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance. <i>Stem Cell Research and Therapy</i> , 2017, 8, 57.	5.5	9
29	CD4 ⁺ CD8 ⁺ double-positive T cells in skin-draining lymph nodes respond to inflammatory signals from the skin. <i>Journal of Leukocyte Biology</i> , 2017, 102, 837-844.	3.3	5
30	Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2017, 3, e171.	1.6	5
31	DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection. <i>Journal of Immunotherapy</i> , 2017, 40, 62-70.	2.4	39
32	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	1.8	42
33	Assessing T cell abundance in cutaneous squamous cell carcinoma: adding another string to your bow. <i>Experimental Dermatology</i> , 2016, 25, 507-508.	2.9	0
34	Interaction between living bone particles and rhBMP-2 in large segmental defect healing in the rat femur. <i>Journal of Orthopaedic Research</i> , 2016, 34, 2137-2145.	2.3	15
35	Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?. <i>International Journal of Cancer</i> , 2016, 138, 281-292.	5.1	38
36	Antigen-Encoding Bone Marrow Terminates Islet-Directed Memory CD8 ⁺ T-Cell Responses to Alleviate Islet Transplant Rejection. <i>Diabetes</i> , 2016, 65, 1328-1340.	0.6	16

#	ARTICLE	IF	CITATIONS
37	Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines. <i>Chemical Science</i> , 2016, 7, 2308-2321.	7.4	24
38	Abstract A064: Modeling checkpoint blockade inhibitor resistant immunoregulation induced by squamous epithelial cancers. , 2016, , .		0
39	Abstract B055: The impact of rapamycin and tacrolimus treatment on resident CD8+ T-cell populations in cutaneous squamous cell carcinoma. , 2016, , .		0
40	Abstract 3999: Altering the balance between immune activation versus regulation in the skin to promote CD8 T-cell activity within epithelial cancers. , 2016, , .		0
41	A novel zinc finger gene, <i>ZNF465</i> , is inappropriately expressed in acute myeloid leukaemia cells. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 288-302.	2.8	1
42	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. <i>Frontiers in Immunology</i> , 2015, 6, 258.	4.8	16
43	HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitis-like lesions. <i>Immunology and Cell Biology</i> , 2015, 93, 540-547.	2.3	10
44	Genetics and nonmelanoma skin cancer in kidney transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 161-172.	1.3	9
45	Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5570-5575.	2.2	6
46	CD4+/CD8+ double-positive T cells: more than just a developmental stage?. <i>Journal of Leukocyte Biology</i> , 2015, 97, 31-38.	3.3	247
47	Rapid and reliable healing of critical size bone defects with genetically modified sheep muscle. , 2015, 30, 118-131.		32
48	Comparative Immune Phenotypic Analysis of Cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in Immune-Competent Individuals: Proportional Representation of CD8+ T-Cells but Not FoxP3+ Regulatory T-Cells Is Associated with Disease Stage. <i>PLoS ONE</i> , 2014, 9, e110928.	2.5	35
49	Do Actinic Keratoses and Superficial Squamous Cell Carcinomas Have a Specific Immunoprofile?. <i>Current Problems in Dermatology</i> , 2014, 46, 36-41.	0.7	3
50	HPV16-E7 Expression in Squamous Epithelium Creates a Local Immune Suppressive Environment via CCL2- and CCL5- Mediated Recruitment of Mast Cells. <i>PLoS Pathogens</i> , 2014, 10, e1004466.	4.7	55
51	Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacy. <i>Blood</i> , 2013, 121, 1049-1058.	1.4	15
52	Inflammatory Cytokines Induce a Unique Mineralizing Phenotype in Mesenchymal Stem Cells Derived from Human Bone Marrow. <i>Journal of Biological Chemistry</i> , 2013, 288, 29494-29505.	3.4	55
53	Arginase Treatment Prevents the Recovery of Canine Lymphoma and Osteosarcoma Cells Resistant to the Toxic Effects of Prolonged Arginine Deprivation. <i>PLoS ONE</i> , 2013, 8, e54464.	2.5	8
54	EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 5341-5351.	7.0	39

#	ARTICLE	IF	CITATIONS
55	Evaluation of BMP gene-activated muscle grafts for cranial defect repair. <i>Journal of Orthopaedic Research</i> , 2012, 30, 1095-1102.	2.3	31
56	Book of Abstracts - Sixteenth International Conference of the Inflammation Research Association, Sunday, September 26 - Wednesday, September 29, 2010 Westfields Marriott, Chantilly, VA, USA. <i>Inflammation Research</i> , 2010, 59, 263-304.	4.0	4
57	Suppression of allergic airway inflammation and IgE responses by a class I restricted allergen peptide vaccine. <i>Mucosal Immunology</i> , 2009, 2, 54-62.	6.0	14
58	Suppression of airway inflammation by a natural acute infection of the intestinal epithelium. <i>Mucosal Immunology</i> , 2009, 2, 144-155.	6.0	10
59	Interleukin-1 β and tumor necrosis factor α inhibit chondrogenesis by human mesenchymal stem cells through NF- κ B-dependent pathways. <i>Arthritis and Rheumatism</i> , 2009, 60, 801-812.	6.7	214
60	Anti-tumor immunity in a model of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 447-454.	1.3	5
61	Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage. , 2009, 18, 96-111.		92
62	Innate responsiveness of CD8 memory T-cell populations nonspecifically inhibits allergic sensitization. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 1014-1021.e4.	2.9	24
63	Combined Triggering of Dendritic Cell Receptors Results in Synergistic Activation and Potent Cytotoxic Immunity. <i>Journal of Immunology</i> , 2008, 181, 3422-3431.	0.8	51
64	Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 226-234.	2.9	54
65	Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1861-1873.	4.2	22
66	Influence of Interleukin-4 on the Phenotype and Function of Bone Marrow-Derived Murine Dendritic Cells Generated Under Serum-Free Conditions. <i>Scandinavian Journal of Immunology</i> , 2005, 61, 251-259.	2.7	33
67	Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. <i>Biochemical and Biophysical Research Communications</i> , 2005, 335, 1293-1304.	2.1	66
68	Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 963-77.	4.2	58